Pharma industry employs 5,600 people in Scotland, report says
A new report has shown that the pharmaceutical industry in Scotland employs nine percent more people now than in 2018.
List view / Grid view
A new report has shown that the pharmaceutical industry in Scotland employs nine percent more people now than in 2018.
A statement from biopharmaceutical industry groups has said they plan to work with regulatory agencies to gather data on COVID-19 vaccines.
A new report has predicted that the global antibiotics market will grow at a CAGR of four percent from 2020-2027.
Over a six year period, the Pfizer-BioNTech COVID-19 vaccine is expected to lead inoculation sales, generating $30 billion.
Amgen has set out the company's seven-year environmental sustainability plan to achieve carbon neutrality by 2027.
Analysts say M&A deals continue to be a core driver of pharma/biopharma industry growth and that 2021 will likely be another year of high deal value.
The MHRA has given the green light to the Moderna COVID-19 vaccine for use in the UK, making it the third to be approved in the country.
Moderna's COVID-19 vaccine has been approved in the EU with a conditional marketing authorisation by the European Commission.
Marta Kalas explains how to develop a COVID Safety Toolkit to ensure pharmaceutical businesses comply with changing regulations.
The new pathway developed by NICE for medicines to go from clinical trials to NHS patients is now in action.
Growth of the global protein crystallisation and crystallography market is attributed to increasing interest in biologics, more investment and advancing technologies.
Brian Pinker was the first person to receive AZD1222, the COVID-19 vaccine developed by the University of Oxford and AstraZeneca, this morning.
Gabriela Marton sets out some of the EU-associated regulatory challenges life sciences companies will need to navigate if they want to take advantage of the rise of biosimilars.
After the US, Europe is considered the second most attractive market for serving patient needs while realising commercial value from innovative drugs. However, the 27 EU member states each have their own approaches to pricing and market access – and need tailored commercialisation and go-to-market strategies. Simon-Kucher & Partners analysed…
Europe will receive an extra 80 million doses of Moderna's mRNA-1273, a COVID-19 vaccine candidate, following the EC's decision.